Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NSE India Stock Exchange  >  Divi's Laboratories Limited    DIVISLAB   INE361B01024

DIVI'S LABORATORIES LIMITED

(DIVISLAB)
  Report
Delayed Quote. Delayed NSE India Stock Exchange - 10/28 07:14:09 am
3131.45 INR   -0.80%
08/10Sensex, Nifty settle higher on pharma boost
RE
05/22DIVI'S LABORATORIES LIMITED : annual earnings release
02/25DIVI'S LABORATORIES LIMITED : Ex-dividend day for interim dividend
FA
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Divi's Laboratories Limited : Press Release Qtr 4 2012-13.

share with twitter share with LinkedIn share with facebook
05/20/2013 | 11:11am EDT

DIVI'S LABORATORIES LIMITED Divi Towers, Dharam Karan Road Hyderabad 500 016

Phone: 23786400 email: kishore@divislaboratories.com

PRESS RELEASE dated 20TH May, 2013

Divi's Labs earns a consolidated Total Income of

Rs.2145 crores in FY13.

Consolidated for the year

Divi's Laboratories has earned a consolidated total income of Rs.2145 crores for the financial year 2012-13 as against a total income of Rs.1864 crores during the last year, reflecting a growth of 15%.
PBT for the current year came to Rs. 781 crores as against a
PBT of Rs.681 crores for the previous year.
Tax for the year is provided at Rs.179 crores as against a tax provision of Rs.147 crores for the previous year.
PAT for the year is Rs. 602 crores as against a PAT of Rs.533 crores for the last year.

Consolidated for the 4th quarter

For the current quarter of the year, the company earned a PAT
of Rs.181 crores on a total income of Rs.658 crores.

Standalone

On a standalone basis, the company's earnings are as given below:

Particulars

For the Quarter

For the year

Current

Previous

Current

Previous

Total

Income

651

711

2129

1845

PBT

239

271

792

695

PAT

182

215

611

546

Operations

The Board has declared a dividend of Rs.15 per share i.e.,
750% subject to approval of members.
Due to the continuing severe power shortage in the State of Andhra Pradesh, the company had to rely on purchased power at higher cost.
Particulars of forex gain/(loss) for the period are given below:

Standalone

Consolidated

Quarter ended

31-03-13

Year

Ended

31-03-13

Quarter ended

31-03-13

Year

Ended

31-03-13

Forex gain/(loss)

(975.10)

1516.40

(777.78)

1145.21

While forex gain has been included in Other Income, forex loss has been included in Other Expenses.
Exports constituted 90% of sales and about 76% to advanced markets in North America and Europe.
During the year, addition to Fixed Assets amounted to Rs.248 crores. In addition, an amount of Rs.303 crores is carried forward as Capital WIP for the Capital Works under execution.
During the year Unit-II facility was successfully inspected by TGA, Australia (GMP), USFDA for Nutraceutical facility, USFDA for API site (pre-approval and cGMP), Slovenian Medicines Agency (EU GMP inspection for 7 APIs).

distributed by

share with twitter share with LinkedIn share with facebook
All news about DIVI'S LABORATORIES LIMITED
08/10Sensex, Nifty settle higher on pharma boost
RE
05/22DIVI'S LABORATORIES LIMITED : annual earnings release
02/25DIVI'S LABORATORIES LIMITED : Ex-dividend day for interim dividend
FA
2019DIVI'S LABORATORIES LTD : Ex-dividend day for final dividend
FA
2018DIVI'S LABORATORIES LTD : Ex-dividend day for final dividend
FA
2017DIVI'S LABORATORIES LTD : Ex-dividend day for final dividend
FA
2016DIVI'S LABORATORIES LTD : Ex-dividend day for interim dividend
FA
2015DIVI'S LABORATORIES LTD : BONUS ISSUE: 1 new share for 1 existing share
FA
2015DIVI'S LABORATORIES LTD : Ex-dividend day for final dividend
FA
2014DIVI'S LABORATORIES LTD : Ex-dividend day for final dividend
FA
More news
Financials
Sales 2021 65 601 M 885 M 885 M
Net income 2021 17 499 M 236 M 236 M
Net cash 2021 3 823 M 51,5 M 51,5 M
P/E ratio 2021 47,7x
Yield 2021 0,59%
Capitalization 831 B 11 204 M 11 208 M
EV / Sales 2021 12,6x
EV / Sales 2022 10,8x
Nbr of Employees -
Free-Float 47,6%
Chart DIVI'S LABORATORIES LIMITED
Duration : Period :
Divi's Laboratories Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DIVI'S LABORATORIES LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 3 250,14 INR
Last Close Price 3 131,45 INR
Spread / Highest target 20,2%
Spread / Average Target 3,79%
Spread / Lowest Target -13,8%
EPS Revisions
Managers
NameTitle
Kiran Satchandra Divi Chief Executive Officer & Executive Director
Ramesh B. V. Nimmagadda Non-Executive Chairman
L. Kishore Babu Chief Financial Officer
L. Ramesh Babu Chief Information Officer & VP-Procurement
Ramesh Babu M. General Manager-Technical Operations
Sector and Competitors